Navana Pharmaceuticals PLC (DSE: NAVANAPHAR)
Bangladesh
· Delayed Price · Currency is BDT 49.80
+0.60 (1.22%)
At close: Nov 14, 2024
Navana Pharmaceuticals Cash Flow Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 |
| Net Income | 440.01 | 356.94 | 274 | 202.29 | 137.4 |
| Depreciation & Amortization | 247.59 | 210.19 | 165.84 | 87.27 | 68.81 |
| Other Amortization | 0.39 | 0.22 | 0.22 | 0.11 | - |
| Loss (Gain) From Sale of Assets | - | - | -0.47 | 0 | - |
| Loss (Gain) From Sale of Investments | 5.48 | 46.8 | -82.9 | - | -19.68 |
| Other Operating Activities | 327.52 | 134.99 | 147.08 | 75.47 | 9.12 |
| Change in Accounts Receivable | -270.02 | -253.42 | -84.93 | -74.38 | 28.94 |
| Change in Inventory | -794.86 | -344.07 | -200.76 | -95.7 | -34.74 |
| Change in Accounts Payable | 442.76 | 152.22 | 79.44 | 8.78 | 3.97 |
| Change in Other Net Operating Assets | -309.97 | -110.13 | -98.16 | -82.11 | 7.69 |
| Operating Cash Flow | 88.89 | 193.74 | 199.36 | 121.75 | 201.5 |
| Operating Cash Flow Growth | -70.78% | -2.82% | 63.74% | -39.58% | - |
| Capital Expenditures | -927.34 | -1,598 | -1,359 | -520.75 | -19.71 |
| Investment in Securities | 15.33 | -2.33 | -171.48 | 53.65 | - |
| Other Investing Activities | 1.15 | 2.79 | 3.26 | -1.17 | - |
| Investing Cash Flow | -910.86 | -1,598 | -1,527 | -468.28 | -19.71 |
| Short-Term Debt Issued | - | 1,384 | 1,551 | 360.66 | - |
| Long-Term Debt Issued | - | - | 17.74 | 93.09 | - |
| Total Debt Issued | 1,032 | 1,384 | 1,569 | 453.75 | - |
| Short-Term Debt Repaid | - | - | - | - | -15.39 |
| Long-Term Debt Repaid | - | -66.46 | -45.83 | -72.02 | -135.3 |
| Total Debt Repaid | 33.82 | -66.46 | -45.83 | -72.02 | -150.69 |
| Net Debt Issued (Repaid) | 1,066 | 1,318 | 1,523 | 381.73 | -150.69 |
| Issuance of Common Stock | - | 750 | - | - | - |
| Common Dividends Paid | -132.95 | -113.15 | - | - | - |
| Other Financing Activities | -253.63 | -175.98 | -154.73 | -64.15 | - |
| Financing Cash Flow | 679.58 | 1,778 | 1,368 | 317.59 | -150.69 |
| Foreign Exchange Rate Adjustments | 0.06 | 0.05 | 0.05 | - | 0 |
| Miscellaneous Cash Flow Adjustments | - | 0 | -0 | - | 0 |
| Net Cash Flow | -142.33 | 374.5 | 40.65 | -28.94 | 31.1 |
| Free Cash Flow | -838.44 | -1,404 | -1,160 | -399 | 181.8 |
| Free Cash Flow Margin | -12.89% | -24.61% | -24.37% | -11.06% | 5.77% |
| Free Cash Flow Per Share | -7.80 | -14.13 | -14.45 | -4.97 | 2.27 |
| Cash Interest Paid | 253.63 | 157.9 | 142.83 | 64.15 | 79.11 |
| Cash Income Tax Paid | 149.57 | 101 | 110.27 | 88.79 | 72.77 |
| Levered Free Cash Flow | -949.94 | -2,414 | -1,836 | -461.76 | - |
| Unlevered Free Cash Flow | -766.57 | -2,267 | -1,711 | -414.77 | - |
| Change in Net Working Capital | 628.3 | 1,331 | 873.8 | 199.27 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.